Verso Corporation (NYSE:VRS) last session’s volume of 0.27 million shares was lower than its average volume of 0.28 million shares. The stock, after opening at $3.65, hit $3.79 through the close by scoring 2.99%.Verso Corporation (VRS) Analyst Opinion
Verso Corporation has a consensus outperform rating from 2 Wall Street analysts, and the number of shares currently sold short amount to at least 2.05% of shares outstanding. The stock sank -10.82% last month and is down -46.62 this year. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover VRS having a buy-equivalent rating. Analysts have placed a $13.13 price target on Verso Corporation, suggesting a 246.44% gain from recent close. It’s currently trading about -72.13% below its 52-week high.Verso Corporation Earnings Surprise
Verso Corporation (VRS) failed to surprise the stock market in its last reported earnings when it earned -$0.61 a piece versus the consensus-estimated -$0.27. Its revenue totaled $615.5 million down -4.72% from the previous quarter.
This stock (VRS) is ahead of its 52-week low with 19.56%. Its last month’s stock price volatility remained 7.72% which for the week stands at 8.35%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.36% and stays -21.5% away from its 50 days moving average. Over the last five days, shares have managed 1.07% gains and now is down -38.94% since hitting its 200-day moving average of $6.17. Verso Corporation (VRS) has made its way to a 12-month decline of 0%.
Turning to Vital Therapies, Inc. (NASDAQ:VTL), its shares were trading at $2.9 a retreat of $-0.1, on the trading floor. The stock, after opening at $2.95, touched a high of $3 before paring much of its gains. So far, analysts are sticking with their bearish recommendations with the consensus call at 3. Vital Therapies, Inc. has 0 buy ratings, 3 holds and 0 sells even after the stock tumbled -64.42% from its high of $7.46 to a $126.61 million market value through last close.Vital Therapies, Inc. (VTL) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 3.25 to 3 during a month. Analysts set a 12-month price target of $7.5 a share. The target implies a 158.62% spike from where the shares are currently trading. Also, the current price highlights a discount of 313.79% to analysts’ high consensus price target.Vital Therapies, Inc. (NASDAQ:VTL) Intraday Trading
The counter witnessed a trading volume of 0.18 million shares versus an average volume of 0.16 million shares during last trading session. Its last month’s stock price volatility remained 8.3% which for the week approaches 12.14%. The lowest price the stock reached in the last trading day was $2.8 and compares with the $2.25 52-week low. The stock recovered 28.89% since its low point and has performed -33.33% year-to-date.